Recently, the "2022 China Biomedical Industry Chain Innovation Billboard" jointly initiated by China Biomedical Industry Chain Innovation and Transformation Alliance, Nanjing Biomedical Industry Innovation and Transformation Center, Yaodu, Yaocurang, Pharmaceutical Progress, and Industrial Securities was officially released at the opening ceremony of the "2nd China Biomedical Industry Chain Innovation and Transformation Summit Forum". A number of invested companies of Ennovation Ventures  were listed on the list.

The awards issued by the "China Biomedical Industry Chain Innovation List" have become a vane award in the field of innovation and transformation of the biomedical industry, and have received great attention and recognition in the industry.

The following are the details of the awards of Ennovation Ventures Partners' portfolio companies:
InxMed is a biotechnology pioneer in the global clinical research and development stage. The company's core layout is the research and development of innovative drugs for the tumor fibrosis microenvironment, focusing on breakthroughs and leading the treatment of solid tumor resistance and metastasis that lack treatment options, taking translational medicine as the source of innovation, giving full play to the advantages of strong clinical capabilities, and becoming a new drug research and development company based in China and influencing the world.
TransThera Sciences (Nanjing), Inc. is a R&D-oriented, clinical-stage global biopharmaceutical company focused on the discovery and development of innovative small molecule therapies in the fields of oncology, inflammation and cardiovascular diseases. TransThera is one of the first developers committed to innovative small molecules in China to establish a global R&D and clinical development platform.
Nanjing Immunophae Technology Co., Ltd. is a clinical-stage biopharmaceutical company, which is a new drug research and development company led by Dr. Fan Guohuang, a Chinese-American scientist, and Dr. Wang Jianfei, a Chinese-Canadian scientist. The company focuses on the research and development of world-leading targets, and is committed to treating global small molecule or large molecule new drugs for major diseases such as malignant tumors, autoimmune diseases, metabolic diseases and neurodegenerative diseases, and continues to achieve milestones in the development of innovative drugs.


Founded in 2018，Nanjing Zenshine Pharmaceuticals Co., Ltd is a clinical-stage biopharmaceutical company with a team of returned technical teams with many years of successful drug research and development experience. Headquartered in Nanjing, it has branches in Hangzhou and the San Francisco Bay Area in the United States, responsible for preclinical and clinical research. Zenshine is committed to solving clinical needs and serving patients，currently focusing on the research and development of small molecule new drugs for cancer, viral infections and autoimmune diseases.
 
Getting this award is a recognition of these companies' innovation capabilities and market competitiveness, as well as an affirmation of Ennovation Ventures' continuous investment in the biomedical field. In the future, Ennovation Ventures  will continue to mobilize industrial resources to empower invested enterprises, promote innovation and transformation in the field of biomedicine, and make greater contributions to the global medical and health industry.